European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes

April 02, 2017

"The European approval of ONGLYZA as combination therapy with insulin helps to advance treatment of type 2 diabetes, by offering physicians another option to help patients manage this chronic and progressive disease," said Howard Hutchinson, M.D., chief medical officer, AstraZeneca.

ONGLYZA is indicated in adult patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin, sulphonylurea, thiazolidinedione or insulin, when each treatment alone, with diet and exercise, does not provide adequate glycaemic control. Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, a lower dose of sulphonylurea or insulin may be required to reduce the risk of hypoglycaemia when used in combination with ONGLYZA.

ONGLYZA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. ONGLYZA is not a substitute for insulin in insulin-requiring patients.

Source Bristol-Myers Squibb and AstraZeneca

©2017 -